Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T‐cell lymphoma and occult cirrhosis
| Autor: | Jason Y. Park, Alain H. Rook, Andrew Avarbock, Jacqueline M. Junkins-Hopkins, John K. Choi, Alison W. Loren, Leslie A. Litzky |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Pathology Cirrhosis Recombinant Fusion Proteins Gastroenterology Liver disease Fatal Outcome Denileukin diftitox Internal medicine medicine Humans Diphtheria Toxin Treatment Failure Vascular Diseases Hypoalbuminemia business.industry Cutaneous T-cell lymphoma Syndrome Hematology Middle Aged medicine.disease Fibrosis Lymphoma T-Cell Cutaneous Lymphoma Interleukin-2 business Complication Rhabdomyolysis medicine.drug |
| Zdroj: | American Journal of Hematology. 83:593-595 |
| ISSN: | 1096-8652 0361-8609 |
| Popis: | Denileukin diftitox (Ontak) is an immunotoxin used in the treatment of cutaneous T-cell lymphomas. Vascular leak syndrome is a known complication of this therapy, although the syndrome is most often self-limited. We report the case of a patient with cutaneous gamma/delta (gammadelta) T-cell lymphoma and previous undiagnosed liver disease treated with denileukin diftitox. Just 4 days after initiating drug therapy, the patient developed profound vascular leak syndrome characterized by a rapid fall in his previously normal serum albumin to levels below the limit of detection. The patient then quickly deteriorated into rhabdomyolysis and eventual death. To our knowledge, this is the first report of a death directly related to denileukin diftitox therapy. The purpose of this case is to increase awareness and improve management of patients who are treated with denileukin diftitox with resulting vascular leak syndrome leading to hypoalbuminemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text